Acorda Therapeutics (ACOR) Misses Q4 EPS by 6c, Sales Beat

Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.05, $0.06 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $140.63 million versus the consensus estimate of $137.9 million.

• AMPYRA® (dalfampridine) 4Q 2016 Net Revenue of $132 Million; Full-Year Net Revenue of $493 Million
• AMPYRA 2017 Net Sales Guidance of $535-$545 Million
• Positive CVT-301 Phase 3 Data Support 2Q 2017 NDA Filing

"The positive Phase 3 data from our pivotal trial of CVT-301 represents a major milestone for Acorda, potentially bringing an important new therapy to people with Parkinson’s,” said Ron Cohen, M.D., Acorda\'s President and CEO. “We plan to file a New Drug Application in the second quarter of 2017, pending the results of two long-term safety studies. Data from these studies are expected in the first quarter of 2017.”

“Our corporate priorities continue to be advancing our Phase 3 Parkinson’s programs and maximizing the value of AMPYRA.”

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c